Alivus Life Sciences Limited

rs,

May 15, 2025 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

1.2%

Yasir Rawjee Managing Director & Chief Executive Officer ( I N ₹ M I L L I O N S ) 6,496 REVENUE 1.2% QoQ 21.1% YoY ( I N ₹ M I L L I O N S ) 2,085 EBITDA 3.8% QoQ 44.2% YoY "FY25 was our first fu

21.1%

ee Managing Director & Chief Executive Officer ( I N ₹ M I L L I O N S ) 6,496 REVENUE 1.2% QoQ 21.1% YoY ( I N ₹ M I L L I O N S ) 2,085 EBITDA 3.8% QoQ 44.2% YoY "FY25 was our first full year und

3.8%

I N ₹ M I L L I O N S ) 6,496 REVENUE 1.2% QoQ 21.1% YoY ( I N ₹ M I L L I O N S ) 2,085 EBITDA 3.8% QoQ 44.2% YoY "FY25 was our first full year under the Nirma ownership. Our overall performance ha

44.2%

L L I O N S ) 6,496 REVENUE 1.2% QoQ 21.1% YoY ( I N ₹ M I L L I O N S ) 2,085 EBITDA 3.8% QoQ 44.2% YoY "FY25 was our first full year under the Nirma ownership. Our overall performance has remained

30%

ions. One of the most encouraging outcomes this year was our ability to maintain EBITDA margins at 30%, even in the absence of PLI benefits and amid market headwinds. This reflects the strength of our d

7.1%

versified portfolio and our continued focus on operational efficiency. Our full-year sales grew by 7.1%, normalizing for the PLI benefit last year and backed by healthy contributions from both GPL and No

₹ 6,496

caling our operations to create long-term value." • Alivus registered a revenue from operations of ₹ 6,496 Mn for Q4FY25, recording a strong growth of 21.1% YoY. • EBITDA margins for the quarter were at 32

32.1%

6 Mn for Q4FY25, recording a strong growth of 21.1% YoY. • EBITDA margins for the quarter were at 32.1%, up 520 bps YoY and 80 bps QoQ, driven by better product mix and new product launches. • Generic

520 bps

4FY25, recording a strong growth of 21.1% YoY. • EBITDA margins for the quarter were at 32.1%, up 520 bps YoY and 80 bps QoQ, driven by better product mix and new product launches. • Generic business gre

80 bps

a strong growth of 21.1% YoY. • EBITDA margins for the quarter were at 32.1%, up 520 bps YoY and 80 bps QoQ, driven by better product mix and new product launches. • Generic business grew by 22.6% YoY

22.6%

and 80 bps QoQ, driven by better product mix and new product launches. • Generic business grew by 22.6% YoY to ₹ 5,941 Mn, whereas CDMO business grew by 22.6% YoY and 44.4% QoQ to ₹ 434 Mn. ( I N ₹ M I

“2 Financial Performance Review 3 3 Q4 FY25 | Highlights Dr.”

“Yasir Rawjee Managing Director & Chief Executive Officer ( I N ₹ M I L L I O N S ) 6,496 REVENUE 1.2% QoQ 21.1% YoY ( I N ₹ M I L L I O N S ) 2,085 EBITDA 3.8% QoQ 44.2% YoY "FY25 was our first full year under the Nirma ownership.”

“As we move into FY26, we remain committed to delivering sustainable growth with stable margins, while continuing to invest in our core growth drivers, expanding our product pipeline, and scaling our operations to create long-term value." • Alivus registered a revenue from operations of ₹ 6,496 Mn for Q4FY25, recording a strong growth of 21.1% YoY.”

“• During FY25, the company generated a strong free cash flow of Rs.”

“4 Q4 & FY25 Performance Revenue ( I n ₹ M illio n s) , 5 8 8 6 , 5 3 6 6 , 5 0 6 9 EBITDA ( In ₹ M illio n s) PAT ( I n ₹ M illio n s) EPS ( I n ₹ ) , 6 4 1 8 6 , 4 9 6 26.9% 28.0% 28.2% , 1 6 5 0 , 1 4 4 6 , 1 4 2 9 31.3% 32.1% , 2 0 0 8 2 , 0 8 5 18.3% 18.9% 18.8% 9 7 9 , 1 1 1 5 9 5 3 21.3% 21.8% , 1 3 7 0 1 , 4 1 9 .”

“7 7 8 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 30.1% 30.0% 20.6% 20.3% , 2 2 8 3 2 FY24 FY25 , 6 8 6 3 FY24 FY25 , 4 7 0 9 FY24 .”

“FY21 FY22 FY23 FY24 FY25 Inventories Days AR days AP days Total WC days 7 Robust Growth & Steady Profitability Revenue ( In ₹ M il li on s ) EBITDA ( In ₹ M illio n s) EBITDA Margin PAT ( In ₹ M illio n s) PAT Margin 31.5% 31.4% 31.1% 30.1% 30.0% , 2 3 8 6 9 , 2 2 8 3 2 , 6 3 0 8 , 5 9 1 9 , 6 7 1 2 , 6 8 6 3 7 , 1 7 2 21.6% 20.6% 20.3% , 4 6 7 0 , 4 7 0 9 4 , 8 5 7 19.7% 18.6% , 4 1 8 7 , 3 5 1 6 , 2 1 2 3 2 , 2 1 6 1 2 , 1 8 8 5 2 EPS ( I n ₹ ) .”

“FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 8 Business Performance Review 9 9 Segmental Performance | Generic API vs CDMO Generic API ( R e ve nu e I n ₹ M illio n s) CDMO ( R e ve nu e I n ₹ M illio n s) 4,846 5,354 4,739 354 5,966 5,941 425 434 300 240 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 • Generic API revenues in Q4FY25 grew by 22.6% YoY.”

“• CDMO business witnessed growth of 22.6% YoY and 44.4% QoQ due to addition of 4th project during the year.”

“7% • 5th project is expected to be commercialized by H2FY26.”

Registered Office

1

REGISTERED OFFICE

1

Registered Office

4th Floor, OIA House, 470, Cardinal Gracious Road Andheri (E), Mumbai 400 099, Maharashtra, India Plot No 170-172, Chandramouli Industrial Estate Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Investor Presentation Q4 & FY25 Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the information purposes only and based on estimates and Presentation. The information contained herein is for general should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are

REGISTERED OFFICE

T: 91 22 68297979 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. CIN: L74900PN2011PLC139963 Website: www.alivus.com 20